Article
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers.
Scientific reports - 11 Mar 2021
Lochrin Sarah E, Turkbey Baris, Gasmi Billel, Schmidt Keith, Strope Jonathan D, Chau Cindy H, Sissung Tristan M, Price Douglas K, Cordes Lisa, Markolovic Suzana, Wood Bradford J, Pinto Peter A, McKinney Yolanda L, Shih Joanna H, Levy Elliot, Madan Ravi, Dahut William, Choyke Peter L, Merino Maria, Figg William D
Abstract excerpt
OATP1B3 is expressed de novo in primary prostate cancer tissue and to a greater degree in prostate cancer metastases. Gadoxetate disodium is a substrate of OATP1B3, and its uptake has been shown to correlate with OATP1B3 expression in other cancers. We aimed to evaluate use of gadoxetate disodium to image prostate cancer and to track its utility as a biomarker. A single center open-label non-randomized pilot...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.